Authors : Harish Kumar E; Dr. Ariharasivakumar Ganesan

Volume/Issue : Volume 10 - 2025, Issue 8 - August

Google Scholar : https://tinyurl.com/2snsmz5w

Scribd : https://tinyurl.com/4w9bv9f8

DOI : https://doi.org/10.38124/ijisrt/25aug1060

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Context: Itraconazole, a triazole antifungal drug, is being explored for its anti-cancer properties through in-silico approaches.  Aims: To investigate the repurposing potential of itraconazole against Skin Cutaneous Melanoma (SKCM) using network pharmacology and molecular docking.  Methods and Material: Target genes were identified using SwissTargetPrediction and TargetNet. SKCM-associated genes were collected from GeneCards, DisGeNET, and OMIM. Protein-protein interaction (PPI) network, GO and KEGG enrichment analyses, gene expression profiling, and docking studies were performed.  Statistical analysis used: Survival analysis and stage-wise expression were assessed using GEPIA2.  Results: Key genes identified included TNF, CASP8, EGFR, MAPK14, MMP9. Docking studies confirmed strong binding with several targets including MMP9 and CASP3.  Conclusions: Itraconazole shows promise as a therapeutic candidate in SKCM via modulation of apoptosis and immune pathways. Further experimental validation is warranted.

Keywords : Itraconazole, Skin Cutaneous Melanoma, Network Pharmacology, in-Silico, Molecular Docking, Gene Expression.

References :

1. Wang Y, Wang L, Wen X, Wei Y, Yang J, Duan J, et al. Itraconazole alleviates neuroinflammation in a mouse model of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun. 2020;521(2):368–374.
2. Oren I, Rowe JM. Treatment of invasive pulmonary aspergillosis with itraconazole in a patient with acute leukemia intolerant to amphotericin B. Clin Infect Dis. 1994;18(3):364–365.
3. Gupta AK, Versteeg SG. A critical review of improvement in quality of life and patient-reported outcomes with topical therapies for superficial fungal infections. J Cutan Med Surg. 2018;22(2):192–199.
4. Wheat LJ, Connolly P, Smedema M, Brizendine E, Hafner R. Emergence of resistance to amphotericin B during treatment of histoplasmosis. Clin Infect Dis. 2001;33(6):E75–E77.
5. Queiroz-Telles F, Santos DW. Challenges in the diagnosis of Sporotrichosis. J Fungi (Basel). 2019;5(3):96.
6. Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388–399.
7. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4(1):18026.
8. Latgé JP, Chamilos G. Aspergillus fumigatus and aspergillosis in 2019. Clin Microbiol Rev. 2020;33(1):e00140-18.
9. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37(3):310–344.
10. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272–279.
11. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2010;50(3):291–322.
12. Dannaoui E. Antifungal resistance in clinically relevant species of filamentous fungi. Mycopathologia. 2017;182(1–2):17–24.
13. Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr, Liu JO. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol. 2007;2(4):263–270.
14. Assi MA, Sandid MS, Baddour LM, Roberts GD, Walker RC. Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients. Medicine (Baltimore). 2007;86(3):162–169.
15. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–690.
16. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11(2):110–120.
17. Zhang GB, Li QY, Chen QL, Su SB. Network pharmacology: a new approach for Chinese herbal medicine research. Evid Based Complement Alternat Med. 2013;2013:621423.
18. Xie L, Wang J, Shen J, Luo X, Zhu W, Liu H, et al. Target-net: a web service for predicting potential drug–target interaction profiling via structural similarity and multiple network strategies. J Chem Inf Model. 2014;54(1):258–266.
19. Zhou W, Wang Y, Lu A, Zhang G. Systems pharmacology in small molecular drug discovery. Int J Mol Sci. 2016;17(2):246.
20. Yao ZJ, Dong J, Che YJ, Zhu MF, Wen M, Wang NN, Wang S, Lu AP, Cao DS. TargetNet: a web service for predicting potential drug–target interaction profiling via multi-target SAR models. Journal of computer-aided molecular design. 2016 May;30:413-24.
21. Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic acids research. 2019 Jul 2;47(W1):W357-64.
22. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-Madi A. GeneCards Version 3: the human gene integrator. Database. 2010 Jan 1;2010:baq020.
23. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic acids research. 2005 Jan 1;33(suppl_1):D514-7.
24. Zaru R, Orchard S, UniProt Consortium. UniProt tools: BLAST, align, peptide search, and ID mapping. Current protocols. 2023 Mar;3(3):e697.
25. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT, Pyysalo S, Bork P. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic acids research. 2023 Jan 6;51(D1):D638-46.
26. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003 Nov 1;13(11):2498-504.
27. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC systems biology. 2014 Dec;8:1-7.
28. Niissalo A. Cytoscape and its Plugins. Department of Computer Science University of Helsinki Finland. 2007 May 25.
29. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic acids research. 2019 Jul 2;47(W1):W556-60.
30. De Wit J, Zonnevylle M, Laforga J, Bugocki R, Kerkhoven R, Spits H, et al. Prognostic significance of epidermal growth factor receptor expression in malignant melanoma. Mod Pathol. 2021;33(5):432–440.
31. Salemi R, Feringa F, Alotta G, Marabeti MR, Giambò F, Scalia G, et al. Functional roles of matrix metalloproteinase 9 in melanoma: biomarker potential and therapeutic target. Tumour Biol. 2020;42(3):101042830.
32. Guarneri V, Rossi E, Ciliberti P, et al. MMP‑9 as a candidate marker of response to BRAF inhibitors in melanoma. Front Pharmacol. 2018;9:856.
33. Tanzola MB, Laborde RR, Moss KJ, et al. EGFR amplification and protein overexpression correlate with poor prognosis in melanoma. Oncotarget. 2025;16(2):150–162.
34. Elder DE, Xu X, Finkelstein SD, Vetto JT, Cochran AJ. EGFR in melanoma: clinical significance and potential therapeutic target. Am J Dermatopathol. 2011;33(4):356–361.
35. Li Y, Zhang B, Wang C, et al. Pan‑cancer analysis reveals MMP9 expression is related to immune modulation and prognostic outcomes. Med (Baltimore). 2023;102(27):e32345.
36. Ge C, Huang H, Huang F, et al. Extracellular HSP90: a novel mediator of cancer cell invasion and immune evasion. Cells. 2022;11(18):2778.
37. Zhang K, Li J, Wang Y, et al. Bioinformatic analysis identifies EGFR as a hub gene in melanoma progression and immune microenvironment regulation. Front Oncol. 2021;11:621430.
38. Wu X, Marmarelis ME, Hodi FS. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS One. 2013;8(2):e56134.
39. Shoushtari AN, Ong LT, Schoder H, et al. Results of a Phase II trial of ganetespib in metastatic melanoma (STA‑9090). Melanoma Res. 2018;28(6):523–528.
40. Liu X, Gong Y, Zhang W, et al. Dual HSP90 and PI3K inhibition in melanoma therapy. Int J Mol Sci. 2020;21(5):1845.